James L Reading PhD; Nature 2026: Regulatory T-Cell Axis Identifies Pre-Malignant Lung Cancer
LONDON, United Kingdom—Researchers in London have identified patterns of regulatory T-cells that give early warning of high risk for lung cancer. The journal Nature has just published research showing that lung cancer could be intercepted through blood tests years ahead of current screening and diagnostics, and treated with safe targeted drugs some of which are already under investigation. Peter Goodwin called into the Pre-cancer Immunology Laboratory at University College London to hear from the senior author of this research, James Reading PhD.
Regulatory T-Cell Axis Identifies Early Pre-Malignant Lung Cancer
An interview with:
James L Reading, Associate Professor of Cancer Immunology, Group Leader, Pre-cancer Immunology Laboratory, University College of London Cancer Institute, London UK
LONDON, United Kingdom—Researchers in London have identified patterns of regulatory T-cells that give early warning of high risk for lung cancer. The journal Nature has just published research showing that lung cancer could be intercepted through blood tests years ahead of current screening and diagnostics and treated with safe targeted drugs, some of which are already under investigation. Peter Goodwin called into the Pre-cancer Immunology Laboratory at University College London to hear from the lead author of this research, James Reading PhD.
AUDIO JOURNAL OF ONCOLOGY: James L Reading PhD
Source:
A preinvasive regulatory T cell axis for lung cancer interception
References
Related Episodes
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA
Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries
CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology. Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.